antibody_engineering

Antibody immunotherapy is transforming cancer care. Biointron explains how antibodies complement traditional treatments to improve patient outcomes.

Engineering CDR loops boosts binding strength. Biointron outlines strategies to optimize CDRs for developing potent therapeutic antibodies.

Somatic hypermutation drives high-affinity antibodies. Biointron explains its role in B cell evolution and therapeutic antibody optimization.

Fully human and humanized antibodies reduce immunogenicity. Biointron highlights their advantages in creating safer, more effective therapeutics.

AbDrop™ isolates diverse, high-affinity antibodies rapidly. Biointron shows how this platform transforms discovery with speed, scale, and precision.

Pharmacokinetics defines antibody behavior in the body. Biointron explains ADME principles and their role in designing effective antibody drugs.

AbDrop™ and HUGO-Ab™ accelerate discovery. Biointron demonstrates how these platforms cut timelines by delivering diverse, high-affinity antibodies faster.

Chimeric antibodies marked a milestone in drug development. Biointron reviews their creation and impact as a foundation for today’s therapeutic antibodies.

Heavy and light chain pairing ensures antigen recognition. Biointron explains its importance in antibody structure, function, and therapeutic application.

Learn about VHH libraries, including their creation, screening methods, structural diversity, and how nanobody technology supports research, diagnostics, and therapeutics.

Explore the role of bispecific antibodies (bsAbs) in cancer therapy and beyond, and learn how dual-targeting enhances immune responses and overcomes monoclonal limits.

Effector functions drive antibody impact. Biointron reviews ADCC, CDC, and other mechanisms that enable antibodies to protect health and guide new therapies.

Discover the unique properties and clinical potential of multispecific antibodies, including tetraspecific formats, advancing next-generation therapeutic strategies.

Learn the difference between ADC biosimilars as cost-effective alternatives to reference drugs and ADC isotypes engineered for distinct therapeutic properties in cancer treatment.

VHH antibodies, also known as nanobodies, are single-domain antibodies that are derived from camelid heavy-chain antibodies. Due to their small size (~ 15 kDa) and diverse applications in bio-derived therapeutics, these antibodies have widespread attention in the research and development community, with some examples below from just this week!